¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Core Binding Factor alpha Subunits"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • protein binding
    ´Ü¹éÁú°áÇÕ
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • sex hormone-binding globulin
    ¼ºÈ£¸£¸ó°áÇձ۷κҸ°
  • antihemophilic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰ÀÎÀÚ
  • antipellagra factor
    Çׯç¶ó±×¶óÀÎÀÚ
  • antiphagocytic factor
    Çׯ÷½ÄÀÎÀÚ, Ç׎½ÄÀÎÀÚ
  • antiplatelet factor
    Ç×Ç÷¼ÒÆÇÀÎÀÚ
  • antirachitic factor
    Ç×±¸·çº´ÀÎÀÚ
  • antiscorbutic factor
    Ç×±«Ç÷º´ÀÎÀÚ
  • antisterility factor
    Ç׺ÒÀÓÀÎÀÚ
  • atrial natriuretic factor
    ½É¹æ³ªÆ®·ýÀÌ´¢ÀÎÀÚ, ½É¹æ¼ÒµãÀÌ´¢ÀÎÀÚ
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • alveolar dilution factor
    ÆóÆ÷Èñ¼®ÀÎÀÚ, ÇãÆÄ²Ê¸®Èñ¼®ÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • alveolar dilution factor
    ÆóÆ÷Èñ¼®ÀÎÀÚ, ÇãÆÄ²Ê¸®Èñ¼®ÀÎÀÚ
  • amplification factor
    ÁõÆøÀÎÀÚ
  • antihemophlic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰ÀÎÀÚ
  • antipellagra factor
    Çׯç¶ó±×¶óÀÎÀÚ
  • antiphagocytic factor
    Çׯ÷½ÄÀÛ¿ëÀÎÀÚ
  • antirachitic factor
    Ç×±¸·íº´ÀÎÀÚ
  • antiscorbutic factor
    Ç×±«Ç÷º´ÀÎÀÚ
  • antisterility factor
    Ç׺ÒÀÓÀÎÀÚ
  • atrial natriuretic factor
    ½É¹æ³ªÆ®·ýÀÌ´¢ÀÎÀÚ
  • colonizing factor antigen
    Áý¶ôÇü¼ºÀÎÀÚÇ׿ø
  • behavioral risk factor
    ÇൿÀ§Çè¿äÀÎ
  • carcinogenic factor
    ¹ß¾ÏÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • alpha fiber
    ¾ËÆÄ(½Å°æ)¼¶À¯
  • alpha granule
    ¾ËÆÄ °ú¸³(¡­Î¨Ø£)
  • alpha hemolysis
    ¾ËÆÄ¿ëÇ÷(¡­éÁúì).
  • alpha hemolysis
    ¾ËÆÄ¿ëÇ÷(¡­éÁúì).
  • alpha hydroxy acids
    ¾ËÆÄÈ÷µå·Ï½Ã»ê
  • alpha motoneuron
    ¾ËÆÄ¿îµ¿´º¿ì·Ð
  • alpha particle
    ¾ËÆÄÀÔÀÚ
  • alpha ray
    ¾ËÆÄ¼±
  • alpha rhythm
    ¾ËÆÄ¸®µë ³úÆÄ(Òà÷î)ÀÇ .
  • alpha thalassemia
    ¾ËÆÄÅ»¶ó¼¼¹Ì¾Æ.
  • alpha thalassemia
    ¾ËÆÄÅ»¶ó¼¼¹Ì¾Æ.
  • alpha thalassemia
    ¾ËÆÄÁöÁßÇØºóÇ÷
  • alpha toxin
    ¾ËÆÄ µ¶¼Ò (¡­Ô¸áÈ)
  • alpha wave
    ¾ËÆÄÆÄ ³úÆÄ(Òà÷î)ÀÇ .
  • alpha-1-antittrypsin deficiensy
    ¾ËÆÄ-1-¾ÈƼƮ¸³½Å °áÇÌÁõ(¡­ÌÀù¹ñø)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • competitive protein binding radioassay
    °æÇÕÀû ´Ü¹é°áÇÕ¹æ»çºÐ¼®(¹ý)(¡­Ó±ÛÜ Ì¿ùêÛ¯ÞÒÝÂà°Ûö).
  • complement binding antibody
    º¸Ã¼°áÇÕÇ×ü(ÜÍô÷Ì¿ùêù÷ô÷).
  • corticosteroid binding globulin =CSG
    ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å°áÇÕ ±Û·ÎºÒ ¸°.
  • cortisol binding globulin
    ÄÚ¸£Æ¼¼Ö°áÇÕ±Û·Îºí¸°.
  • cortisol-binding globulin=transcortin
    ÄÚ¸£Æ¼¼Ö°áÇձ۷κҸ°=Æ®¶õ½ºÄÚ¸£Æ¾
  • cross binding
    ±³Â÷¿¬°á(±³Â÷¿¬°á).
  • human zona binding assay
    »ç¶÷Á¤ÀÚ Åõ¸í´ëºÎÂø°Ë»ç
  • iron binding capacity =IBC
    ö°áÇÕ´É(ôÑÌ¿ùêÒö).
  • iron binding protein =IBP
    ö°áÇÕ ´Ü¹éÁú.
  • iron-binding capacity
    ö°áÇÕ´É
  • orthodontic binding wire =o. ligature wire
    ±³Á¤¿ë °áÂû¼±(ÎìïáéÄÌ¿óÏàÊ).
  • penicillin binding protein (PBP)
    Æä´Ï½Ç¸° °áÇմܹéÁú
  • periplasmic binding protein
    ¿øÇüÁú¸· ÁÖÀ§°ø°£ °áÇմܹéÁú
  • plasma protein binding
    Ç÷Àå´Ü¹é°áÇÕ.
  • protein binding
    (Ç÷Àå)´Ü¹é°áÇÕ.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • latent iron-binding capacity
    ÀáÀçö°áÇÕ´É(íÖî¤ôÑÌ¿ùêÒö)
  • macroscopic binding constant
    °Å½Ã °áÇÕ»ó¼ö(ËÝãÊÌ¿ùêßÈâ¦)
  • microscopic binding constant
    ¹Ì½Ã°áÇÕ»ó¼ö(Ú°ãÊÌ¿ùêßÈâ¦)
  • mononucleotide binding domain
    ¸ð³ë´©Å¬·¹¿ÀŸÀÌµå °áÇÕ¿µ¿ª(Ì¿ùêÖÅæ´)
  • multiple binding
    ´ÙÁß°áÇÕ(ÒýñëÌ¿ùê)
  • nonexclusive binding
    ºñ¹èŸ°áÇÕ(ÞªÛÉöâÌ¿ùê)
  • nonexclusive binding coefficient
    ºñ¹èŸ°áÇÕ»ó¼ö(ÞªÛÉöâÌ¿ùêßÈâ¦)
  • nucleotide-binding domain
    ´©Å¬¸®¿ÀŸÀÌµå °áÇÕ¿µ¿ª(Ì¿ùêÖÅæ´)
  • retinol-binding protein
    ·¹Æ¼³î °áÇÕ ´Ü¹éÁú(Ì¿ùêÓ±ÛÜòõ)
  • ribosome binding site
    ¶óÀ̺¸¼Ø °áÇÕ(Ì¿ùê)ÀÚ¸®
  • ribosome binding technique
    ¶óÀ̺¸¼Ø °áÇÕ¼ú(Ì¿ùêâú)
  • sex hormoe binding globulin
    ¼º(àõ)È£¸£¸ó °áÇÕ(Ì¿ùê)±Û·ÎºÒ¸°
  • sex steroid binding plasma protein
    ¼º(àõ)½ºÅ×·ÎÀÌµå °áÇÕ(Ì¿ùê) Ç÷Àå(úìíì) ´Ü¹éÁú(úìíìÓ±ÛÜòõ)
  • single-strand binding protein
    ¿Ü°¡´Ú °áÇմܹéÁú(Ì¿ùêÓ±ÛÜòõ)
  • single-stranded DNA binding protein
    ¿Ü°¡´Ú DNA °áÇմܹéÁú(Ì¿ùêÓ±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
IBP insulin-like growth factor binding protein; International Biological Program; intra-aortic balloon p...
DF decapacitation factor; decontamination factor; deferoxamine; deficiency factor; defined flora [anima...
GRF gastrin-releasing factor; genetically related macrophage factor; gonadotropin-releasing factor; grow...
HSF heat shock factor; hepatocyte stimulatory factor; histamine sensitizing factor; human serum esterase...
LPF leukocytosis-promoting factor; leukopenia factor; lipopolysaccharide factor; localized plaque format...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
SDF-1 alpha Stromal derived factor-1 alpha
TNF alpha Tumour Necrosis Factor alpha
TGF alpha Transforming Growth Factor alpha
eIF-2 alpha eukaryotic initiation factor 2 alpha
nHuTNF-alpha natural human tumor necrosis factor alpha
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • alpha-oxynaphthoic acid
    ¾ËÆÄ-¿Á½Ã³ªÇÁÅä»ê
    °áÁ¤¼ºÀÇ »ê,OHC10H6COOH.°ú°Å¿¡´Â ¹æºÎÁ¦, ¹æÃëÁ¦·Î »ç¿ëµÇ¾ú´Ù.
  • { alpha }`_{2 } ^{A } { gamma }`_{ 2} ^{F }

    ¶ó°í ±âÀçµÈ´Ù. Çì¸ð±Û·Îºó A(¼ºÀÎ Çì¸ð±Û·Îºó)´Â º¸Åë ¼ºÀÎÀÇ ´ëºÎºÐÀÌ µÇ¸ç,
    ¿ëÇ÷¼º
    Çì¸ð±Û·ÎºóÀÌ ÀûÇ÷±¸¿¡¼­ À¯¸®ÇÏ¿© Ç÷ÀåÁß¿¡ ³ªÅ¸³ª´Â ¼ºÁú.
  • myelinated A alpha mechanoreceptor
    À¯¼öÃÊ A-¾ËÆÄ ±â°è ¼ö¿ëü, À¯¼öÃÊ A-¾ËÆÄ ±â°è ¼ö¿ë±â
  • absorbed dose conversion factor
    Èí¼ö¼±·® º¯È¯ °è¼ö
  • accessory food factor
    ¿µ¾ç º¸Á¶ ÀÎÀÚ
    F.G Ho
  • air kerma calibration factor
    °ø±â Ä¿¸¶ ÃøÁ¤ °è¼ö, ´«±Ý ¸ÂÃã °è¼ö
  • alveolar dilution factor
    ÆóÆ÷ Èñ¼® ÀÎÀÚ
  • angiogenesis factor
    Ç÷°ü Çü¼º ÀÎÀÚ
    ½Å»ý Ç÷°ü Áõ½ÄÀ» À¯µµÇÏ´Â ¹°Áú·Î¼­, Á¾¾çÀ̳ª ¸Á¸· °°Àº ½ÅÁø´ë»ç·®ÀÌ Å« Á¶Á÷¿¡¼­ ¹ß°ßµÈ´Ù. ÀÌ ÀÎÀÚ´Â »óóÀÇ °¡ÀåÀÚ¸®³ª Ç¥¸é¿¡ ÀÖ´Â Àú»ê¼Ò »óÅÂÀÇ ´ë½Ä¼¼Æ÷¿¡¼­ ºÐºñµÇ¸ç, »óó Ä¡À¯ °úÁ¤¿¡¼­ Ç÷°ü ÀçÇü¼ºÀ» À¯µµÇÑ´Ù.
  • anisotropy factor
    ºñµî¹æ¼º °è¼ö
  • antiangiogenesis factor
    Ç×Ç÷°ü»ý¼º ÀÎÀÚ
    Harvard ´ëÇп¡¼­ ¿¬±¸µÈ °ÍÀε¥ ¿¬°ñ¿¡´Â ¸ð¼¼Ç÷°üÀÌ Ä§ÅõµÇÁö ¾Ê´Â Çö»óÀ» °üÂûÇÏ°í ¾Ï Á¶Á÷¿¡ ¿¬°ñÁ¶Á÷¿¡¼­ À¯·¡µÈ antiangiogenesis factor¶ó´Â °ÍÀ» »ç¿ëÇÏ¿© ¾Ï Á¶Á÷ÀÇ ¼èÅ𸦠ÃÊ·¡ÇÏ¿´´Ù.
  • antihemophilic factor
    Ç×Ç÷¿ìº´ ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰 ÀÎÀÚ
  • antistiffness factor
    Ç×°­Á÷ ÀÎÀÚ
  • atrial natriuretic factor
    ½É¹æ¼º ³ªÆ®·ý ÀÌ´¢ ÀÎÀÚ
  • attenuation factor
    °¨¾à ¿ä¼Ò, °¨¼è ¿äÀÎ
  • CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
    androgen-binding proteins Carrier proteins produced in the sertoli cells of the testis, secreted into the seminiferous tubules, and transported via the efferent ducts to the epididymis. Participate in the transport of androgens; include also synthetic androgens binding proteins.
    (12 Dec 1998)
    antigen-binding site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
    Also used of the site on a ligand molecule to which a cell surface receptor binds.
    (18 Nov 1997)
    binding <biochemistry, chemistry, molecular biology> The adherence of molecules to one another, for example, enzymes to substrates, antibodies to antigens, DNA strands to their complementary strands.
    Binding occurs because the shape and chemical natures of parts of the molecules surfaces are complementary. A common metaphor is the "lock-and-key," used to describe how enzymes fit around their substrate.
    (14 Nov 1997)
    binding constant <chemistry> Reciprocal of dissociation constant. A measure of the extent of a reversible association between two molecular species at equilibrium.
    (18 Nov 1997)
    binding energy <chemistry, radiobiology> The binding energy of a nucleus is the minimum energy required to dissociate it into its component neutrons and protons. Neutron or proton binding energies are those required to remove a neutron or proton, respectively, from a nucleus. Electron binding energy is that required to remove an electron from an atom or a molecule.
    (16 Dec 1997)
    binding sites The reactive parts of a macromolecule that directly participate in its specific combination with another molecule.
    (12 Dec 1998)
    binding sites, antibody Local surface sites on antibodies which react with antigen determinant sites on antigens. They are formed from parts of the variable regions of the fab fragment of the immunoglobulin.
    (12 Dec 1998)
    calcium-binding protein <biochemistry> There are two main groups of calcium binding proteins, those that are similar to calmodulin and are called EF hand proteins and those that bind calcium and phospholipid (e.g. Lipocortin) and that have been grouped under the generic name of annexins.
    Many other proteins will bind calcium, although the binding site usually has considerable homology with the calcium-binding domains of calmodulin. They can act as transport proteins, regulator proteins or activator proteins.
    There is also a vitamin D-dependent variant which is a protein that plays a fundamental role in the vitamin d mediated transport of calcium in reptiles, amphibians, birds and mammals. It is found in the intestine, kidneys, egg shell gland, brain, and possibly other organs. Its molecular weight is species dependent.
    (12 May 2002)
    calmodulin-binding proteins Proteins which bind calmodulin. They are found in many tissues and have a variety of functions including f-actin cross-linking properties, inhibition of cyclic nucleotide phosphodiesterase and calcium and magnesium atpases.
    (12 Dec 1998)
    cap binding protein <molecular biology, protein> Protein (24 kD) with affinity for cap structure at 5' end of mRNA that probably assists, together with other initiation factors, in binding the mRNA to the 40S ribosomal subunit. Translation of mRNA in vitro is faster if it has a cap binding protein.
    (18 Nov 1997)
    galactose binding protein <protein> A bacterial periplasmic protein, most studied in E. Coli, that acts both as a sensory element in the detection of galactose as a chemotactic signal and in the uptake of the sugar.
    (18 Nov 1997)
    Raji cell binding test <investigation> A test for the detection of soluble IgG antigen complexes. Raji cells are a line of EBV transformed lymphocytes with surface Fc receptors. Complexes are detected by their ability to compete with a radiolabelled aggregated IgG for binding to the cells.
    (18 Nov 1997)
    maltose binding protein <protein> Protein of the bacterial (E. Coli) surface that links with MCP II and is involved in the chemotactic response to maltose, probably derived from a similar protein that links with a trans membrane transport system.
    (18 Nov 1997)
    vitamin d-binding protein An alpha-globulin found in the plasma of man and other vertebrates. It is apparently synthesised in the liver and carries vitamin d and its metabolites through the circulation and mediates the response of tissue. It is also known as group-specific component (gc). Gc subtypes are used to determine specific phenotypes and gene frequencies. These data are employed in the classification of population groups, paternity investigations, and in forensic medicine.
    (12 Dec 1998)
    cellular retinoic acid binding protein <protein> A cytoplasmic fatty acid binding protein that acts as an initial receptor for the putative morphogen, retinoic acid.
    (18 Nov 1997)
    ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    • releasing factor
      È£¸£¸ó ¹æÃâÀÎÀÚ
    • rheumatoid factor
      ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
    ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
    KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • Á¦Ç°¸í
      ¼ººÐ/ÇÔ·®
      ±¸ºÐ/º¸Çè±Þ¿©
    KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • Á¦Ç°¸í
      ¼ººÐ/ÇÔ·®
      ±¸ºÐ/º¸Çè±Þ¿©
    ¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    ¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
      ÇÑÀÚ
    ´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
      ÇÑÀÚ
    ´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ÄÚµå
      ¿µ¹®
      ÇѱÛ
    Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ÄÚµå
      ¿µ¹®
      ÇѱÛ
    °æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
      ¼³¸í
    CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
    MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
    Á¦Ç°¸í
    ÆÇ¸Å»ç
    º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
    ¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
    Á¦Ç°¸í
    ÆÇ¸Å»ç
    º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
    ¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
    KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    • ¿µ¹®
      ÇѱÛ
    WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
    ¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
    ÅëÇÕ°Ë»ö ¿Ï·á